Safety testing of new adjuvants, once combined with a vaccine, necessitates improved and consistent standards for safety monitoring boards, post-licensure signal generation and evaluation, and surveillance of adverse immunological events.

• 新型佐剂的安全性检测(一旦与疫苗联合)需要更为完善和统一的安全监测委员会标准、上市许可后“(警报)信号发生”和评价标准以及不良免疫反应事件监测标准。